These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

280 related articles for article (PubMed ID: 35661906)

  • 1. Anti-MDA5 dermatomyositis after COVID-19 vaccination: a case-based review.
    Gonzalez D; Gupta L; Murthy V; Gonzalez EB; Williamson KA; Makol A; Tan CL; Sulaiman FN; Shahril NS; Isa LM; Martín-Nares E; Aggarwal R
    Rheumatol Int; 2022 Sep; 42(9):1629-1641. PubMed ID: 35661906
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antimelanoma Differentiation-Associated Gene 5 Antibody-Positive Interstitial Lung Disease After Vaccination With COVID-19 mRNA Vaccines.
    Kitajima T; Funauchi A; Nakajima T; Marumo S; Imura Y; Fukui M
    J Rheumatol; 2022 Oct; 49(10):1158-1162. PubMed ID: 35705246
    [TBL] [Abstract][Full Text] [Related]  

  • 3. MDA5-autoimmunity and interstitial pneumonitis contemporaneous with the COVID-19 pandemic (MIP-C).
    David P; Sinha S; Iqbal K; De Marco G; Taheri S; McLaren E; Maisuria S; Arumugakani G; Ash Z; Buckley C; Coles L; Hettiarachchi C; Payne E; Savic S; Smithson G; Slade M; Shah R; Marzo-Ortega H; Keen M; Lawson C; Mclorinan J; Nizam S; Reddy H; Sharif O; Sultan S; Tran G; Wood M; Wood S; Ghosh P; McGonagle D
    EBioMedicine; 2024 Jun; 104():105136. PubMed ID: 38723554
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Anti-MDA5 autoantibodies predict clinical dynamics of dermatomyositis following SARS-CoV-2 mRNA vaccination: a retrospective statistical analysis of case reports.
    Klein CR; Heine A; Brossart P; Karakostas P; Schäfer VS
    Rheumatol Int; 2024 Oct; 44(10):2185-2196. PubMed ID: 39190200
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Different Multivariable Risk Factors for Rapid Progressive Interstitial Lung Disease in Anti-MDA5 Positive Dermatomyositis and Anti-Synthetase Syndrome.
    Zuo Y; Ye L; Chen F; Shen Y; Lu X; Wang G; Shu X
    Front Immunol; 2022; 13():845988. PubMed ID: 35320936
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rituximab in the Treatment of Interstitial Lung Diseases Related to Anti-Melanoma Differentiation-Associated Gene 5 Dermatomyositis: A Systematic Review.
    He C; Li W; Xie Q; Yin G
    Front Immunol; 2021; 12():820163. PubMed ID: 35116041
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical spectrum and therapeutics in Canadian patients with anti-melanoma differentiation-associated gene 5 (MDA5)-positive dermatomyositis: a case-based review.
    Huang K; Vinik O; Shojania K; Yeung J; Shupak R; Nimmo M; Avina-Zubieta JA
    Rheumatol Int; 2019 Nov; 39(11):1971-1981. PubMed ID: 31375890
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fatal outcome of anti-MDA5 juvenile dermatomyositis in a paediatric COVID-19 patient: a case report.
    Quintana-Ortega C; Remesal A; Ruiz de Valbuena M; de la Serna O; Laplaza-González M; Álvarez-Rojas E; Udaondo C; Alcobendas R; Murias S
    Mod Rheumatol Case Rep; 2021 Jan; 5(1):101-107. PubMed ID: 33019894
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Predictors of Poor Outcome of Anti-MDA5-Associated Rapidly Progressive Interstitial Lung Disease in a Chinese Cohort with Dermatomyositis.
    Li Y; Li Y; Wu J; Miao M; Gao X; Cai W; Shao M; Zhang X; Xu Y; Cong L; He J; Sun X
    J Immunol Res; 2020; 2020():2024869. PubMed ID: 33299896
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Anti-melanoma differentiation-associated gene 5 (MDA5) antibody-positive dermatomyositis responds to rituximab therapy.
    Ge Y; Li S; Tian X; He L; Lu X; Wang G
    Clin Rheumatol; 2021 Jun; 40(6):2311-2317. PubMed ID: 33411136
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Low positive titer of anti-melanoma differentiation-associated gene 5 antibody is not associated with a poor long-term outcome of interstitial lung disease in patients with dermatomyositis.
    Sakamoto S; Okamoto M; Kaieda S; Fujimoto K; Nagata S; Tominaga M; Nakamura M; Zaizen Y; Nouno T; Koga T; Kawayama T; Kuwana M; Ida H; Hoshino T
    Respir Investig; 2018 Nov; 56(6):464-472. PubMed ID: 30150008
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lung transplantation for anti-MDA5-positive dermatomyositis-associated rapid progressive interstitial lung disease: report of two cases and review of the literature.
    Lian QY; Chen A; Zhang JH; Xu X; Huang DX; Luo Q; He JX; Ju CR
    Clin Rheumatol; 2023 Mar; 42(3):941-947. PubMed ID: 36441397
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Roles of biomarkers in anti-MDA5-positive dermatomyositis, associated interstitial lung disease, and rapidly progressive interstitial lung disease.
    Li X; Liu Y; Cheng L; Huang Y; Yan S; Li H; Zhan H; Li Y
    J Clin Lab Anal; 2022 Nov; 36(11):e24726. PubMed ID: 36221983
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comprehensive assessment of myositis-specific autoantibodies in polymyositis/dermatomyositis-associated interstitial lung disease.
    Hozumi H; Fujisawa T; Nakashima R; Johkoh T; Sumikawa H; Murakami A; Enomoto N; Inui N; Nakamura Y; Hosono Y; Imura Y; Mimori T; Suda T
    Respir Med; 2016 Dec; 121():91-99. PubMed ID: 27888997
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Neutrophil extracellular traps may contribute to interstitial lung disease associated with anti-MDA5 autoantibody positive dermatomyositis.
    Peng Y; Zhang S; Zhao Y; Liu Y; Yan B
    Clin Rheumatol; 2018 Jan; 37(1):107-115. PubMed ID: 28842784
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Adolescent-onset anti-MDA5 antibody-positive juvenile dermatomyositis with rapidly progressive interstitial lung disease and spontaneous pneumomediastinum: a case report and literature review.
    Yeung TW; Cheong KN; Lau YL; Tse KN
    Pediatr Rheumatol Online J; 2021 Jun; 19(1):103. PubMed ID: 34193210
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Anti-MDA5 antibody-positive dermatomyositis with rapidly progressive interstitial lung disease: report of two cases.
    Mehta AA; Paul T; Cb M; Haridas N
    BMJ Case Rep; 2021 Apr; 14(4):. PubMed ID: 33910791
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Coexistence of Anti-Ro52 Antibodies in Anti-MDA5 Antibody-Positive Dermatomyositis Is Highly Associated With Rapidly Progressive Interstitial Lung Disease and Mortality Risk.
    Lv C; You H; Xu L; Wang L; Yuan F; Li J; Wu M; Zhou S; Da Z; Qian J; Wei H; Yan W; Zhou L; Wang Y; Yin S; Zhou D; Wu J; Lu Y; Su D; Liu Z; Liu L; Ma L; Xu X; Zang Y; Liu H; Ren T; Wang F; Zhang M; Tan W
    J Rheumatol; 2023 Feb; 50(2):219-226. PubMed ID: 35705235
    [TBL] [Abstract][Full Text] [Related]  

  • 19. MDA5 expression is associated with TGF-β-induced fibrosis: potential mechanism of interstitial lung disease in anti-MDA5 dermatomyositis.
    Shen N; Zhou X; Jin X; Lu C; Hu X; Zhang Y; Jiang Y; Xu Q; Xu X; Liu M; Lu L; Han Y
    Rheumatology (Oxford); 2022 Dec; 62(1):373-383. PubMed ID: 35412608
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Utility of anti-melanoma differentiation-associated gene 5 antibody measurement in identifying patients with dermatomyositis and a high risk for developing rapidly progressive interstitial lung disease: a review of the literature and a meta-analysis.
    Chen Z; Cao M; Plana MN; Liang J; Cai H; Kuwana M; Sun L
    Arthritis Care Res (Hoboken); 2013 Aug; 65(8):1316-24. PubMed ID: 23908005
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.